// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























3952 Abstracts

Efficacy of First- & Second-Line Treatment in an In Vivo Model of Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas

R. Alva-Ruiz - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Cisplatin

CITATION Study Protocol: A Prospective Study Aimed to Test the Feasibility of Neoadjuvant Immuno- and Chemo-Therapy in Locally Advanced CCA

A. Belli - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cisplatin

A Patient-Level Comparison of Systemic Chemotherapy and Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

S. Franssen - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Advanced biliary tract carcinoma

Cisplatin

Pancreatic carcinosarcoma: a rare case report and systematic review of the literature

N.K. Dave - International Hepato-Pancreato-Biliary Association (IHPBA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adenosquamous carcinoma

Cisplatin

Neoadjuvant Chemotherapy in Locally Advanced Unresectable Carcinoma Gall Bladder (ENACT Trial): A Novel Beginning in a Tertiary Centre in North India

S. Galodha - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Paediatric Pancreaticoduodenectomy: Case Report and Intraoperative Footage

J. McGarry - International Hepato-Pancreato-Biliary Association (IHPBA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Beckwith–Wiedemann syndrome

Cisplatin

YB-1 AS A BIOMARKER FOR DRUG RESISTANCE AND TUMOUR PROGRESSION IN MEDULLOBLASTOMA

Louisa Taylor - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mismatch repair deficiency

Cisplatin

ASSESSMENT OF BRAIN PENETRANCE, BIODISTRIBUTION, AND EFFICACY OF PLATINUM (IV)-CONJUGATED FLUORINATED MACROCYCLIC CELL-PENETRATING PEPTIDES IN A MURINE GLIOBLASTOMA MODEL

Jorge Jimenez Macias - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Cisplatin

CASE REPORT OF CISPLATIN + ETOPOSIDE FOR THE TREATMENT OF METASTATIC MALIGNANT MENINGIOMA

Minhdan Nguyen - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

Cisplatin

ID8 OVARIAN CANCER MOUSE MODEL MIMICS NEUROLOGICAL SEQUELAE OF OVARIAN CANCER IN WOMEN

Naomi Lomeli - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Cisplatin

A PREDICTIVE MICROFLUIDIC MODEL OF VASCULARIZED GLIOMA TUMORS TO ASSESS TRAFFICKING OF THERAPEUTICS ACROSS THE BLOOD-BRAIN BARRIER

Cynthia Hajal - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Cisplatin

Y-BOX BINDING PROTEIN 1 REGULATES MEDULLOBLASTOMA TUMOR BIOLOGY AND THERAPEUTIC RESPONSE

Leon McSwain - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Medulloblastoma

Cisplatin

TREATING DIPG WITH A MITOCHONDRIALLY TARGETED PLATINUM(IV)-BASED PRODRUG

Sudhir Raghavan - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Tuberculosis

Cisplatin

THE THERAPEUTIC POTENTIAL OF THE LONG NON-CODING RNA LNC-HLX-2-7 IN GROUP 3 MEDULLOBLASTOMAS IN CHILDREN

Keisuke Katsushima - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Medulloblastoma

Cisplatin

NEUROLOGICAL SEQUELAE IN THE ID8 OVARIAN CANCER MOUSE MODEL: P38/JNK MAPK INHIBITION AS A POTENTIAL THERAPEUTIC FOR CANCER-RELATED COGNITIVE IMPAIRMENTS AND CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Naomi Lomeli - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Peripheral neuropathy

Cisplatin

Pregnancy and Cervical Cancer – Case Report in the Pathological Pregnancy Ward of the IMIP

Gabriela C. C. Bivar - International Federation of Gynecology and Obstetrics (FIGO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Deep vein thrombosis

Cisplatin

Eribulin inhibits cell growth in cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft harboring TP53 and ARID2 mutations

C. Hsu - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cutaneous squamous cell carcinoma

Cisplatin

Eribulin has anti-tumor activity in a preclinical model of merkel cell carcinoma

K. Miyamoto - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Merkel cell carcinoma

Cisplatin

Inhibition of HMGB1 attenuates the inflammatory response in keratinocytes

K.G. Bui - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

Cisplatin

Biological and in-silico characterization of pyrazole and pyrazolone derivatives: Identifies novel anti-skin cancer, antioxidant and tyrosinase inhibitory agents

S.T. Boateng - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Skin carcinoma

Cisplatin

Copyright © 2026. QuantiNova All rights reserved